http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

tirosint is l thyroxine t4 indicated for adults and pediatric patients 6 years and older with hypothyroidism as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 1 pituitary thyrotropin thyroid stimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropin dependent well differentiated thyroid cancer 1 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine sufficient patients 1 not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis 1 hypothyroidism tirosint is indicated as a replacement therapy in adults and pediatric patients 6 years and older with primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism pituitary thyrotropin thyroid stimulating hormone tsh suppression tirosint is indicated as an adjunct to surgery and radioiodine therapy in the management of adults and pediatric patients 6 years and older with thyrotropin dependent well differentiated thyroid cancer limitations of use tirosint is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine sufficient patients as there are no clinical benefits and overtreatment with tirosint may induce hyperthyroidism see warnings and precautions 5 4 tirosint is not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_1459 DOID_1459

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00451 drugbank:DB00451

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-28T06:08:46.641Z

http://purl.org/np/RAjTSUbmyU... RAjTSUbmyU

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-28T06:08:46.641Z